Tag Archives: DOACs

It is hoped that PROACs might become the first anticoagulants suitable for long-term co-administration with antiplatelet drugs for patients with coronary artery disease due to their novel combination of efficacy, low bleeding, and sparing of platelet function that was observed in preclinical testing. Many patients worldwide could potentially benefit from safe, long-term therapy combining an oral anticoagulant with one or more antiplatelet drugs (e.g. aspirin, clopidogrel) to prevent stroke or heart attack. Some of these drugs can be addictive and addiction treatment can help over come this addiction. Current combination treatments with direct